Lv36
204 积分 2022-05-11 加入
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
3天前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
3天前
已完结
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis
4天前
已完结
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis
4天前
已完结
Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial
3个月前
已完结
Low-dose interleukin-2 in the treatment of refractory relapsing polychondritis
3个月前
已完结
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up
3个月前
已完结
Cancer incidence and mortality in China, 2022
3个月前
已完结
Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
3个月前
已完结
Injection site reactions with the use of biological agents
3个月前
已完结
皖公网安备34019202002308
